Medexus Pharmaceuticals Inc. (TSX:MDP)

Medexus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	5.34	6.52	23.97	5.26	13.07	10.02
Cash & Short-Term Investments	5.34	6.52	23.97	5.26	13.07	10.02
Cash Growth	-42.73%	-72.79%	356.19%	-59.79%	30.45%	-46.44%
Accounts Receivable	12.98	14.78	13.17	23.87	21.97	13.39
Other Receivables	0.11	0.08	0.14	0.16	0.41	1.02
Receivables	13.09	14.86	13.31	24.03	22.38	14.41
Inventory	29.87	36.87	39.82	36.72	22.85	21.35
Prepaid Expenses	10.58	5.09	3.1	4.19	12.38	2.06
Other Current Assets	-	0.45	0.38	2.3	2.3	1.28
Total Current Assets	58.89	63.78	80.57	72.5	72.97	49.11
Property, Plant & Equipment	0.37	0.42	0.69	0.78	0.9	1.22
Goodwill	10.05	10.14	10	10.28	10.28	10.69
Other Intangible Assets	61.87	62.34	71.6	64.14	70.37	76.57
Long-Term Deferred Tax Assets	10.92	10.6	8.98	8.04	6.81	-
Other Long-Term Assets	-	-	-	-	-	1.64
Total Assets	142.09	147.28	171.84	155.73	161.33	139.23

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	38.21	8.22	5.73	7.75	10.16	12.05
Accrued Expenses	-	38.33	35.42	35.48	23.26	17.13
Current Portion of Long-Term Debt	2.39	2.21	36.79	15.74	42.71	15.05
Current Portion of Leases	-	-	0.19	-	-	-
Current Income Taxes Payable	1.84	2.12	1.37	1.32	1.18	0.03
Other Current Liabilities	2.7	2.7	17.81	5.94	6.19	3.86
Total Current Liabilities	45.14	53.58	97.31	66.23	83.5	48.11
Long-Term Debt	23.65	19.79	-	33.61	26.78	39.03
Long-Term Leases	0.21	0.26	0.2	0.54	0.6	0.78
Long-Term Deferred Tax Liabilities	-	-	-	-	-	1.52
Other Long-Term Liabilities	25.02	24.66	22.19	25.03	28.01	31.99
Total Liabilities	94.03	98.29	119.7	125.41	138.88	121.43

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	94.02	95.56	96.1	76.39	69.01	68.69
Additional Paid-In Capital	11.87	11.72	12.01	12.01	11.31	10.38
Retained Earnings	-63.85	-64.39	-62	-64.24	-64.03	-65.25
Comprehensive Income & Other	6.03	6.1	6.03	6.17	6.16	3.97
Shareholders' Equity	48.07	48.99	52.14	30.32	22.45	17.79
Total Liabilities & Equity	142.09	147.28	171.84	155.73	161.33	139.23

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	26.25	22.26	37.18	49.9	70.08	54.86
Net Cash (Debt)	-20.91	-15.74	-13.21	-44.64	-57.01	-44.84
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.65	-0.49	-0.50	-2.00	-2.78	-2.26
Filing Date Shares Outstanding	31.5	31.66	32.26	24.46	20.25	19.95
Total Common Shares Outstanding	31.5	32.03	32.26	24.46	20.18	19.95
Working Capital	13.74	10.2	-16.74	6.27	-10.53	1
Book Value Per Share	1.53	1.53	1.62	1.24	1.11	0.89
Tangible Book Value	-23.85	-23.49	-29.46	-44.09	-58.21	-69.46
Tangible Book Value Per Share	-0.76	-0.73	-0.91	-1.80	-2.88	-3.48
Machinery	-	1.12	1.26	1.12	1.07	1.06

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 27, 2026

Data Sources Report a data error